Premium
Clinical significance of cathepsin D assay in breast cancer tissues
Author(s) -
Itoh Yukashi,
Kobayashi Shunzo,
Iwase Hirotaka,
Yamashita Hiroko,
Kuzushima Tatsuya,
Iwata Hiroji,
Yamashita Toshinari,
Naitoh Akihiro,
Itoh Kazuko,
Masaoka Akira
Publication year - 1995
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930600402
Subject(s) - cathepsin d , breast cancer , medicine , univariate analysis , oncology , pathology , immunohistochemistry , cancer , lymph node , estrogen receptor , cancer research , multivariate analysis , biology , enzyme , biochemistry
Cathepsin D was assayed in 74 primary breast cancer specimens by enzyme immunoassay (EIA) and immunohistochemical assay (ICA). Of the 74 specimens, 38 (51.4%) were scored positive by ICA, and 25 (33.8%) were scored positive by EIA. The coincidence rate between ICA and EIA was 71.6% (53/74). There was no significant correlation between cathepsin D and menopausal status, tumor size, number of metastatic lymph nodes, histologic type of the tumor, or steroid receptor status. Cathepsin D status designated by EIA or ICA predicted neither disease‐free survival (DFS) nor overall survival (OAS). Subset analysis with estrogen receptor, menopausal, and lymph node status revealed no association between cathepsin D and survival. Univariate analysis revealed no association between cathepsin D and DFS or OAS. Therefore, cathepsin D is not an independent prognostic factor in breast cancer. © 1995 Wiley‐Liss, Inc.